Cisplatin plus Gemcitabine Chemotherapy in Taxane/Anthracycline-Resistant Metastatic Breast Cancer

Abstract

Background: The most commonly used chemotherapeutic regimens in the treatment of metastatic breast cancer (MBC) include anthracyclines and taxanes. In our study, we investigated the efficacy and tolerability of cisplatin plus gemcitabine combination chemotherapy regimen in patients with MBC, who exhibited disease progression after anthracycline- and taxane-based chemotherapy. Methods: Thirty-three patients with taxane/anthracycline-resistant MBC have been treated with gemcitabine 1,000 mg/m² intravenously and cisplatin 30 mg/m² intravenously on days 1 and 8 of a 3-week treatment cycle. Results: Thirty-one patients were assessable for response. One of the 31 patients (3.2%) showed complete response, while 7 patients (22.6%) showed partial response; the objective response rate was 25.8%. Stable and progressive disease was observed in 6 (19.4%) and 17 patients (54.8%), respectively. The median time to progression was 4 months (95% CI 2.15–5.85). The median survival time of all patients was 9.5 months (95% CI 7.86–11.14). Conclusion: Gemcitabine and cisplatin combination therapy is moderately active and safe in patients with MBC previously treated with anthracycline and taxanes.

Cisplatin Plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases: a Preferential Option for Triple Negative Patients?

“…Gemcitabine is a chemotherapeutic agent that acts as a pyrimidine nucleoside antimetabolite, which has relatively low toxicity and as a single agent it achieves 14-37% of response rates (RR) as first-line and approximately 25% RR as salvage therapy (Carmichael et al, 1995;Brodowicz et al, 2000;Spielmann et al, 2001;Valerio et al, 2001). The combination of Cisplatin and Gemcitabine was investigated in several studies on patients with metastatic breast cancer (MBC); and 26-63% of RR were shown in those studies (Doroshow et al, 2000;Galvez et al, 2000;Nagourney et al, 2000;Heinemann et al, 2002;Somali et al, 2009). Herein, we investigated the efficacy of Cisplatin-Gemcitabine combination therapy in a subset of breast cancer patients with BM.…”

Involvement of Insulin-Like Growth Factor-I Secretion and <i>All-Trans-</i>Retinoic Acid-Induced Decrement in Viability in MCF-7 Cells

“…Thus, there are a number of strategies in the administration of chemotherapeutic drugs used today [2,3]. However, it has been reported that breast cancer has some acquired resistance [1,4], and ineffectiveness of anticancer drugs is frequently observed in cancer chemotherapy [5].…”

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

“…The median TTP varied between 3.2 and 7.7 months, and median OS ranged from 7.4 to 19.5 months. The major toxicities were myelosuppression, peripheral neuropathy and nausea/vomiting (table 4) [83,84,85,86,87,88,89,90,91,92]. In the study by Nagourney et al [83], 13% of patients had grade III/IV neutropenia, 6% had anemia, 31% had thrombocytopenia, 4% had nausea/vomiting and 2% had peripheral neuropathy.…”

“…In the study by Nagourney et al [83], 13% of patients had grade III/IV neutropenia, 6% had anemia, 31% had thrombocytopenia, 4% had nausea/vomiting and 2% had peripheral neuropathy. Most studies observed that this regimen is well tolerated, with grade III/IV leukopenia and thrombocytopenia being the most serious adverse events and nonhematological toxicity rarely being severe [86,87,88,89,90,91,92]. …”